Last reviewed · How we verify
levofloxacin-based triple therapy
Levofloxacin-based triple therapy combines a fluoroquinolone antibiotic with two other agents to eradicate Helicobacter pylori infection by inhibiting bacterial DNA gyrase and topoisomerase IV.
Levofloxacin-based triple therapy combines a fluoroquinolone antibiotic with two other agents to eradicate Helicobacter pylori infection by inhibiting bacterial DNA gyrase and topoisomerase IV. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | levofloxacin-based triple therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Fluoroquinolone antibiotic (in combination therapy) |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Levofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in H. pylori. In triple therapy formulations, levofloxacin is combined with additional antimicrobial agents (typically amoxicillin and a proton pump inhibitor, or similar combinations) to achieve synergistic bacterial eradication and reduce antibiotic resistance. This combination approach targets H. pylori through multiple mechanisms simultaneously.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Headache
- Tendinopathy (fluoroquinolone class effect)
Key clinical trials
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq (NA)
- Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (PHASE4)
- H. Pylori Screen-and-treat Study in a Population of Young Adults
- Eradication of H. Pylori Infection With Moxifloxacin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: